CMAJ • May 25, 2004; 170 (11). doi:10.1503/cmaj.1030418.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suh, K. N.
Right arrow Articles by Keystone, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suh, K. N.
Right arrow Articles by Keystone, J. S.
Related Collections
Right arrow Travel Medicine
Right arrow Malaria

Malaria

Kathryn N. Suh, Kevin C. Kain and Jay S. Keystone

From the Division of Infectious Diseases, Children's Hospital of Eastern Ontario, and Department of Pediatrics, University of Ottawa, Ottawa, Ont. (Suh); the McLaughlin Centre for Molecular Medicine, University of Toronto (Kain); the Centre for Travel and Tropical Medicine, Division of Infectious Diseases, Toronto General Hospital and the University of Toronto (Kain, Keystone), Toronto, Ont.


View this table:

[in a new window]
 
Table 1.

 


View larger version (39K):

[in a new window]
 
Fig. 1: Global distribution of malaria. Drug resistance is represented by the shaded areas (see legend). This map is intended as a visual aid only; online sources of country-specific malaria risk are provided in "Additional Resources." Reproduced, with permission, from the Committee to Advise on Tropical Medicine and Travel, Health Canada. Canadian recommendations for the prevention and treatment of malaria among international travellers — 2003. Can Commun Dis Rep 2004;30(Suppl 1). In press.

 


View larger version (141K):

[in a new window]
 
Fig. 2: The plasmodia life cycle. The human (asexual) stage of the life cycle begins with the exoerythrocytic phase. When an infected mosquito bites a human, sporozoites in the mosquito's saliva enter the bloodstream (1). The sporozoites travel to the liver, where they invade hepatocytes (2); over a period of up to 4 weeks, the infected hepatocytes mature into schizonts. In Plasmodium vivax and P. ovale infections only, some schizonts may remain dormant as hypnozoites (3) for weeks to years before causing clinical relapses. With schizont rupture, merozoites are released into the bloodstream (4). In the erythrocytic phase, merozoites invade erythrocytes and either undergo an asexual cycle of reproduction (5) or develop into nonmultiplying sexual forms (gametocytes) (6). These gametocytes are crucial for perpetuating the life cycle, as they are ingested by a feeding mosquito (7) and undergo sexual reproduction within the mosquito midgut; thousands of infective sporozoites (8) are produced, which then migrate to the salivary glands, ready to initiate another life cycle. Photo: Lianne Friesen and Nicholas Woolridge

 


View larger version (51K):

[in a new window]
 
Fig. 3: Stages in the life cycle of Plasmodium falciparum. A: Ring forms (early trophozoites). B: Mature schizont, rarely seen in peripheral blood smears because of microvascular sequestration. C: Gametocyte, demonstrating the classic banana shape. Source: Division of Parasitic Diseases, US Centers for Disease Control and Prevention, Atlanta. Photo: CDC

 

View this table:

[in a new window]
 
Table 2.

 

View this table:

[in a new window]
 
Table 3.

 

View this table:

[in a new window]
 
Table 4.

 

View this table:

[in a new window]
 
Table 6.

 

View this table:

[in a new window]
 
Table 5.